Skip to main content

Table 1 Overview of studies that estimate the minimal clinically important difference (MCID) for the six-minute walk test (6MWT)

From: Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome

  Reference Disease N Mean baseline 6MWT distance (m) MCID determination method
      Anchor-based Distribution-based
1 & 2 du Bois, 2010 [29] & du Bois, 2011 [30] IPF 822 392 x x
3 Swigris, 2010 [31] IPF 154a 373 x x
4 Holland, 2009 [42] Diffuse parenchymal lung disease 48b 403 x x
5 Holland, 2010 [43] COPD 75 359 x x
6 Polkey, 2013 [32] COPD 2112 369 x  
7 Puhan, 2008 [51] COPD 460 361   x
8 Puhan, 2011 [44] COPD 1218 348 x x
9 Redelmeier, 1997 [45] COPD 112 371 x  
10 Wise, 2005 [52] Emphysema (COPD) 470 353   x
11 Lee, 2014 [46] Non-cystic fibrosis bronchiectasis 37 551 x x
12 & 13 Gremeaux, 2011 [48] and [47] CAD 81 NA x x
14 Gilbert, 2009 [53] PAH 207 339–347   x
15 Mathai, 2012 [49] PAH 405 343 x x
16 Henricson, 2013 [28] DMD 24 370 x  
17 McDonald, 2013 [54] DMD 174 358   x
18 Kwok, 2013 [50] Frail elderly Asian persons 73 295 x x
19 Taeger, 2013 [55] CHF NA NA NA NA
  1. CAD coronary artery disease, CHF chronic heart failure, COPD chronic obstructive pulmonary disease, DMD Duchenne muscular dystrophy, IPF idiopathic pulmonary fibrosis, MCID minimal clinically important difference, NA not available, PAH pulmonary arterial hypertension
  2. aOnly 123 patients had data at baseline and follow-up
  3. b24 patients had IPF
\